Assess novelty of the mechanism of action of new antimicrobial solutions
Pharmaceutical industries have a huge interest in developing new antimicrobials with new mechanisms of action (MoA) in order to fight antimicrobial resistance.
Characterizing MoA along a drug development process, from hit to preclinical, is very complex and involves combinations of technologies. Reference assessment methods of early-stage MoA novelty are labor-intensive and costly.
As expressed by Pharmas, the need is « A more economical and faster technology, to perform alternative phenotypic screening of molecules, and able to treat complex therapeutic solutions”
BIOASTER proposes a phenotypic, cost-effective, rapid (<2h), and label-free technology to classify antimicrobial modes of action and assess MoA novelty from time-lapse quantitative phase images of incubated bacteria.
The technology relies on time-lapse Digital Inline Holographic Microscopy coupled with artificial intelligence.
The robust, label-free sample preparation guarantees genericity and minimal impairment of the bacterial behavior, while the single-cell approach enables sub-population specificity to be detected. No limitation regarding molecule combinations or phages is expected.
BIOASTER brought together advanced optics (computational microscopy approaches) and artificial intelligence experts (Deep convolutional neural network), intending to assess fast classification and novelty assessment of antimicrobial modes of actions on the basis of label-free quantitative phase imaging of a treated bacterial target.
We have developed a full pipeline from sample preparation, incubation image database acquisition, time-lapse image processing and deep-learning based algorithms for classifying main existing modes of actions. Novelty assessment tool is under development.
We are impatient of sharing the results of this proof of concept with partners looking for developing new antimicrobial solutions